Nothing Special   »   [go: up one dir, main page]

WO2010067374A3 - Polymorphs of dasatinib - Google Patents

Polymorphs of dasatinib Download PDF

Info

Publication number
WO2010067374A3
WO2010067374A3 PCT/IN2008/000822 IN2008000822W WO2010067374A3 WO 2010067374 A3 WO2010067374 A3 WO 2010067374A3 IN 2008000822 W IN2008000822 W IN 2008000822W WO 2010067374 A3 WO2010067374 A3 WO 2010067374A3
Authority
WO
WIPO (PCT)
Prior art keywords
dasatinib
solvate
preparation
present
provides
Prior art date
Application number
PCT/IN2008/000822
Other languages
French (fr)
Other versions
WO2010067374A2 (en
Inventor
Bandi Parthasaradhi Reddy
Kura Rathnakar Reddy
Rapolu Raji Reddy
Dasari Muralidhara Reddy
Thungathurthy Srinivasa Roa
Original Assignee
Hetero Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Research Foundation filed Critical Hetero Research Foundation
Priority to PCT/IN2008/000822 priority Critical patent/WO2010067374A2/en
Publication of WO2010067374A2 publication Critical patent/WO2010067374A2/en
Publication of WO2010067374A3 publication Critical patent/WO2010067374A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a novel crystalline form I of dasatinib, process for its preparation and to pharmaceutical composition containing it. The present invention also provides dasatinib dimethylformamide solvate, dasatinib dimethyl sulfoxide solvate, dasatinib toluene solvate and dasatinib isopropyl acetate solvate, processes for its preparation. The present invention further provides a process for preparation of crystalline dasatinib monohydrate.
PCT/IN2008/000822 2008-12-08 2008-12-08 Polymorphs of dasatinib WO2010067374A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2008/000822 WO2010067374A2 (en) 2008-12-08 2008-12-08 Polymorphs of dasatinib

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2008/000822 WO2010067374A2 (en) 2008-12-08 2008-12-08 Polymorphs of dasatinib

Publications (2)

Publication Number Publication Date
WO2010067374A2 WO2010067374A2 (en) 2010-06-17
WO2010067374A3 true WO2010067374A3 (en) 2011-05-26

Family

ID=42243139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000822 WO2010067374A2 (en) 2008-12-08 2008-12-08 Polymorphs of dasatinib

Country Status (1)

Country Link
WO (1) WO2010067374A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101891738B (en) * 2010-02-08 2011-09-28 南京卡文迪许生物工程技术有限公司 Dasatinib polymorph and preparation method and medical composition thereof
WO2012014149A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited N-methylformamide solvate of dasatinib
CN102030745B (en) * 2010-11-26 2012-05-09 江苏先声药物研究有限公司 Dasatinib solvate and preparation method thereof
CN102086195B (en) * 2011-01-28 2013-04-03 南京卡文迪许生物工程技术有限公司 Dasatinib polymorphic substance as well as preparation method and medicinal composition thereof
CN102898424A (en) * 2011-07-29 2013-01-30 江苏奥赛康药业股份有限公司 Novel polymorphs of dasatinib, and preparation method thereof
CN103059013B (en) * 2011-10-18 2016-11-23 北京本草天源药物研究院 Crystal formation of Dasatinib monohydrate and preparation method thereof
WO2013065063A1 (en) 2011-11-03 2013-05-10 Cadila Healthcare Limited Anhydrous form of dasatinib, process for its preparation and its use
CN104379582A (en) * 2012-06-15 2015-02-25 巴斯夫欧洲公司 Multicomponent crystals comprising dasatinib and selected cocrystal formers
CN103833745A (en) * 2012-11-22 2014-06-04 上海博悦生物科技有限公司 New polycrystalline substance alpha form of dasatinib monohydrate and preparation method thereof
CZ306598B6 (en) 2012-12-06 2017-03-22 Zentiva, K.S. A method of preparation and purification of new and known polymorphs and dasatinib solvates
CN103880833B (en) * 2012-12-19 2018-04-06 北京本草天源药物研究院 New crystalline form of Dasatinib monohydrate and preparation method thereof and pharmaceutical composition
AU2014295143B9 (en) 2013-07-25 2017-03-23 Basf Se Salts of Dasatinib in amorphous form
AU2014295144B2 (en) 2013-07-25 2017-06-15 Basf Se Salts of Dasatinib in crystalline form
WO2016001025A1 (en) 2014-06-30 2016-01-07 Basf Se Multicomponent crystals of dasatinib with menthol or vanillin
CN105055327A (en) * 2015-07-30 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 Dasatinib composite granules capable of treating leukaemia
CN104997737A (en) * 2015-08-05 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 Composition dry suspension of medicine dasatinib tablet for treating leukemia
US9168226B1 (en) 2015-08-07 2015-10-27 David Wong Injectable particle
CN105055367A (en) * 2015-08-18 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 SprycelTM composition capsule medicine for treating leukemia
WO2017108605A1 (en) 2015-12-22 2017-06-29 Synthon B.V. Pharmaceutical composition comprising amorphous dasatinib
CN107033137A (en) * 2016-02-03 2017-08-11 正大天晴药业集团股份有限公司 A kind of crystal formation of Dasatinib and preparation method thereof
EP3649126A4 (en) 2017-07-07 2021-04-07 Biocon Limited Polymorphic forms of dasatinib
WO2019209908A1 (en) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Crystalline forms of dasatinib
TW202421157A (en) 2018-06-15 2024-06-01 漢達生技醫藥股份有限公司 Use of cabozantinib lauryl sulfate salt dosage form for treating thyroid cancer, renal cell carcinoma or hepatocellular carcinoma
US10799459B1 (en) 2019-05-17 2020-10-13 Xspray Microparticles Ab Rapidly disintegrating solid oral dosage forms containing dasatinib

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077945A2 (en) * 2004-02-06 2005-08-25 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2009053854A2 (en) * 2007-10-23 2009-04-30 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
WO2010062715A2 (en) * 2008-11-03 2010-06-03 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077945A2 (en) * 2004-02-06 2005-08-25 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2009053854A2 (en) * 2007-10-23 2009-04-30 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
WO2010062715A2 (en) * 2008-11-03 2010-06-03 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof

Also Published As

Publication number Publication date
WO2010067374A2 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
WO2010067374A3 (en) Polymorphs of dasatinib
WO2009053854A3 (en) Polymorphs of dasatinib and process for preparation thereof
WO2010139981A3 (en) Processes for preparing crystalline forms of dasatinib
WO2010014883A3 (en) Azacitidine process and polymorphs
WO2009006590A3 (en) Docetaxel process and polymorphs
ME02026B (en) New crystalline form V of agometaline, the process for its preparation and the pharmaceutical compositions containing it
EP2457908B8 (en) Process for the Preparation of Compounds useful as inhibitors of SGLT
PL2210872T3 (en) New crystalline form iii of agometalin, the process for its preparation and pharmaceutical compositions containing it
WO2008092954A3 (en) Polymorphic forms of a macrocyclic inhibitor of hcv
WO2009140624A3 (en) Glucokinase activators
WO2007104034A3 (en) Glucokinase activators
WO2008079787A3 (en) Glucokinase activators
WO2008116107A3 (en) Piperazine derivatives as glucokinase activators
WO2010062715A3 (en) Polymorphs of dasatinib and process for preparation thereof
WO2011048604A3 (en) Processes for the preparation of darunavir and the amorphous form thereof
EP2518039B8 (en) Method for the preparation of therapeutically valuable triphenylbutene derivatives
WO2009104021A3 (en) Novel polymorphs and processes for their preparation
WO2011024192A3 (en) Novel polymorphs of raltegravir
WO2010011834A3 (en) Process for the preparation of sunitinib malate via sunitinib acetate and their polymorphs
WO2010129636A3 (en) Lenalidomide polymorph
WO2007098273A3 (en) Novel crystalline forms of armodafinil and preparation thereof
WO2009037538A3 (en) Process for the preparation of lamivudine form i
WO2007013043A3 (en) Processes for the preparation of 7-amino-3-vinyl cephalosporanic acid
WO2010146595A3 (en) Novel polymorphs of flibanserin hydrochloride
WO2008062253A3 (en) Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 4350/CHENP/2009

Country of ref document: IN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08878693

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08878693

Country of ref document: EP

Kind code of ref document: A2